<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="140980">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265667</url>
  </required_header>
  <id_info>
    <org_study_id>CF101-202PS</org_study_id>
    <nct_id>NCT01265667</nct_id>
  </id_info>
  <brief_title>Trial of CF101 to Treat Patients With Psoriasis</brief_title>
  <official_title>A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Can-Fite BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Can-Fite BioPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16
      weeks. All subjects will receive open-lable CF101 in weeks 17-32.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be randomly assigned to parallel dosing groups of CF101 2 mg or
      matching placebo tablets twice daily (BID) in a 1:1 ratio for the 16-week controlled
      treatment period. Approximately 94 patients will be assigned to each group.

      Medication will be taken orally BID for 16 weeks in a double-blinded fashion. At the end of
      16 weeks, all patients assigned to CF101 will continue CF101, while patients originally
      assigned to placebo will be reassigned to CF101.

      Assessment of peripheral blood mononuclear cell (PBMC) adenosine A3 receptor (A3AR)
      expression at baseline and during treatment with CF101 in selected sites.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving PASI 75 at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving PGA of 0 or 1</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients achieving Psoriasis Area and Severity (PASI) score of 50 and 75</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature and frequency of adverse events</measure>
    <time_frame>32 weeks</time_frame>
    <description>Assessment of safety of CF101 in this patient population by gathering adverse event data based on history, vital signs, physical examination, and laboratory data</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>CF101 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF101</intervention_name>
    <description>orally q12h</description>
    <arm_group_label>CF101 2 mg</arm_group_label>
    <other_name>IB-MECA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>orally q12h</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Dummy pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 to 80 years of age, inclusive

          -  Diagnosis of moderate-to-severe chronic plaque-type psoriasis with body surface area
             involvement ≥10%

          -  Duration of psoriasis of at least 6 months

          -  PGA ≥3

          -  Candidate for systemic treatment or phototherapy for psoriasis

          -  ECG is normal

          -  Females of child-bearing potential must have a negative serum pregnancy test

          -  Females of child-bearing potential must be willing to use 2 methods of contraception

          -  Ability to complete the study in compliance with the protocol

          -  Ability to understand and provide written informed consent.

        Exclusion Criteria:

          -  Erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis

          -  Treatment with systemic retinoids, corticosteroids, or immunosuppressive agents
             within 4 weeks of the Baseline visit

          -  Treatment with high potency topical corticosteroids, keratolytics, or coal tar within
             2 weeks of the Baseline visit

          -  Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit

          -  Treatment with a biological agent within a period of time equal to 5 times its
             circulating half-life

          -  Treatment with lithium, hydroxychloroquine or chloroquine within 2 weeks of the
             Baseline visit

          -  Serum creatinine level greater than 1.5 times the laboratory's upper limit of normal

          -  Liver aminotransferase levels greater than the laboratory's upper limit of normal

          -  Significant acute or chronic medical or psychiatric illness

          -  Participation in another investigational drug or vaccine trial concurrently or within
             30 days prior to Screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Silverman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Can-Fite BioPharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;G.stranski&quot;</name>
      <address>
        <city>Pleven</city>
        <zip>5800,</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Tokuda hospital Sofia&quot;</name>
      <address>
        <city>Sofia,</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCC &quot;Fokus-5&quot;-MIOC, EOOD</name>
      <address>
        <city>Sofia,</city>
        <zip>1463</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Acdemy (MMA)</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Doverie&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1632,</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Center for Skin and Venereal Disease</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Ttreatment</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Varna at MMA Sofia</name>
      <address>
        <city>Varna,</city>
        <zip>9010,</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haemek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tiqva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Euromed</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Dermato-Venerice</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency County Clinical Hospital</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Constanta</name>
      <address>
        <city>Constanta,</city>
        <zip>900622</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spit Clinic Judetean de Urgenta Sf Spiridon Iasi</name>
      <address>
        <city>Iasi</city>
        <zip>700368,</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Clinical Emergency Hospital</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Israel</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.canfite.com/</url>
    <description>Can-Fite BioPharma website</description>
  </link>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 1, 2015</lastchanged_date>
  <firstreceived_date>December 9, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Plaque psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
